X0303 4 2009-10-15 1 0000005187 WYETH WYE 0001187311 STEIN LAWRENCE V 5 GIRALDA FARMS MADISON NJ 07940 0 1 0 0 Sr. VP and General Counsel Common Stock 2009-10-15 4 D 0 37398.6164 D 0 D Common Stock (401(k)) 2009-10-15 4 D 0 4540.82 D 0 I By 401(k) Plan Common Stock (Restricted Stock Trust) 2009-10-15 4 D 0 5550.3535 D 0 I Restricted Stock Trust Employee Stock Option 56.5938 2009-10-15 4 D 0 25500 0.00 D Common Stock 25500 0 D Employee Stock Option 56.525 2009-10-15 4 D 0 27500 0.00 D Common Stock 27500 0 D Employee Stock Option 60.705 2009-10-15 4 D 0 28000 0.00 D Common Stock 28000 0 D Employee Stock Option 41.05 2009-10-15 4 D 0 20000 8.53 D Common Stock 20000 0 D Employee Stock Option 40.22 2009-10-15 4 D 0 40000 9.36 D Common Stock 40000 0 D Employee Stock Option 43.57 2009-10-15 4 D 0 54000 6.01 D Common Stock 54000 0 D Employee Stock Option 48.22 2009-10-15 4 D 0 72000 1.36 D Common Stock 72000 0 D Employee Stock Option 56.00 2009-10-15 4 D 0 79200 0.00 D Common Stock 79200 0 D Employee Stock Option 44.56 2009-10-15 4 D 0 87000 5.02 D Common Stock 87000 0 D Phantom Stock Units 2009-10-15 4 D 0 1147.91 D Common Stock 1147.91 0 I SESP Pursuant to the Agreement and Plan of Merger by and among Wyeth, Pfizer Inc. and Wagner Acquisition Corp., dated as of January 25, 2009 (as amended, the "Merger Agreement"), each of these shares was cancelled at the effective time of the merger and converted into the right to receive $33.00 in cash and 0.985 of a share of Pfizer Inc. common stock, less any applicable tax withholding. Represents an estimate of the common stock equivalents underlying the reporting person's holdings of units in the Wyeth common stock fund in the Wyeth 401(k) plan as of a recent date. Each share in the Wyeth common stock fund in the Wyeth 401(k) was cancelled at the effective time of the merger and converted into the right to receive $33.00 in cash and 0.985 of a share of Pfizer Inc. common stock. Pursuant to the Merger Agreement, each outstanding and unexercised option, whether vested or unvested, was cancelled at the effective time of the merger in exchange for cash equal to the product of (a) the number of shares underlying such option and (b) the excess, if any, of the per share value of the merger consideration of $49.58 over the per share exercise price of the option, less any applicable tax withholding. Pursuant to the Merger Agreement, each phantom stock unit in the Supplemental Employee Savings Plan ("SESP") was converted at the effective time of the merger into the the right to receive an amount equal to notional $33.00 in cash plus 0.985 of a phantom share of Pfizer Inc. common stock in accordance with the SESP. Represents phantom stock units in the SESP. Tara J. Gabbai, Attorney-in-Fact for Lawrence V. Stein 2009-10-19